Technologies Available for Licensing
NYVAC-BASED PLASMODIUM MALARIA VACCINE
The disclosure generally provides a WRrNYVAC comprising multiple antigens from different stages of a malaria parasite (Plasmodium) life cycle, methods for producing them, immunogenic vaccine formulations comprising WRrNYVAC, such as P. vivax containing formulations (WRPvrNYVAC) and P. falciparum containing formulations (WRPfrNYVAC) and methods for the prevention and/or treatment of malaria infections and poxvirus infections.
Docket:WRAIR 16-18-US02
Publication/Issued No.:11,013,791
Publication/Issue Date:2021-05-25
Categories: Vaccine
More Detail:Visit USPTO.GOV
Lab:WRAIR
Inventor(s):HAUNS, K.